UBS Starts Charles River Labs (CRL) at Neutral
More News related to CRL
- Charles River Promotes Foster Jordan to Corporate Senior Vice President
- Matrix Lighthouse Rating Changes 11/17
- CCR Technologies Ltd. Reports Third Quarter 2008 Results
- Charles River Reschedules 2009 Guidance Release
- Charles River Labs (CRL) Reports Mixed Q3 Earnings; Cuts FY08 Outlook
More News related to New Coverage
- SCIA Announces "LOWER PRICES" for Attendees This Saturday
- Kari Boiler Named President of Bugaboo Americas
- 2009: Faith Popcorn's New Rules of Engagement
- Lance, Inc. Announces Successful Bid to Purchase Assets of Archway Cookies LLC
- Infoteria Online Releases Korean Language Version of Online Stickies lino
UBS initiates coverage on Charles River Laboratories (NYSE: CRL) with a Neutral rating.
Charles River Laboratories International, Inc., together with its subsidiaries, provides solutions that advance the drug discovery and development process, including research models and associated services, and outsourced preclinical services worldwide.
Related Categories
New CoverageStocks Mentioned
-0.14Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
